Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Eye Diseases

Rare Diseases

Melanoma

Eye Neoplasms

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Ocular Melanoma

Neuroendocrine Tumor

Neuroepithelioma

Antipyretics

Analgesics

All Drugs and Chemicals

Anti-Infective Agents

Antineoplastic Agents

Acetaminophen

Interferons

Interferon-alpha

Interferon alpha-2

Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.

Pegylated Interfon Alpha 2B

Placebo

Hans Grossniklaus, MD

The purpose of this study is to explore whether the drug pegylated-interferon-alfa-2b (PEG-IFN) has any effect on a certain type of immune cell (called natural killer cells) in patients with eye melanoma.

The purpose of this study is to explore whether the drug pegylated-interferon-alfa-2b (PEG-IFN)has any effect on a certain type of immune cell (called natural killer cells) in patients with eye melanoma. Because this drug is currently being investigated for use against skin melanoma, we think this drug might have some benefit in eye melanoma as well, and that natural killer cells might be important in how the drug works.

Patients who choose to take part in the study will be randomized to receive either no drug, or PEG-IFN. Four days prior to the patient's surgery to remove the eye, 50cc of blood will be drawn. Patients who are randomized to PEG-IFN will be given the drug once, 4 days prior to surgery. Blood will also be drawn on the day of surgery (50cc), 1 week after surgery (50cc), 1 month (500cc), and 6 months (50cc).

Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye

Exploratory Trial of Interferon Alpha-2b in Neoadjuvant Treatment of Ocular Melanoma

Emory University

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye	NCT00621439	Ocular Melanoma	Pegylated Inter... Placebo	18 Years -	Emory University
Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye	NCT00621439	Ocular Melanoma	Pegylated Inter... Placebo	18 Years -	Emory University

Spots Global Cancer Trial Database for pegylated interfon alpha 2b